Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | F12 | P00748 | 9/20 | 0.32 |
| ▸ | F2 | P00734 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17075122 | 0.90 | NLRP3 (0.33) | NLRP3F12SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17075095 | 0.89 | F12 (0.33) | F12F2ALDH1A1HPGDBCHE | |
| SCHEMBL17075140 | 0.78 | PRCP (0.37) | BCHE | |
| SCHEMBL17075088 | 0.75 | ALDH1A1 (0.49) | ALDH1A1HPGD | |
| SCHEMBL2764864 | 0.73 | BCHE (0.34) | F12F2ALDH1A1BCHE | |
| SCHEMBL17078368 | 0.70 | IDO1 (0.36) | NLRP3SLC6A2SLC6A4SLC6A3KDM4E | |
| SCHEMBL5355843 | 0.69 | NLRP3 (0.40) | NLRP3KDM4EALDH1A1HPGD | |
| SCHEMBL1804490 | 0.69 | CHRNB4 (0.37) | F12BCHE | |
| SCHEMBL1804494 | 0.69 | CHRNB4 (0.37) | F12BCHE | |
| SCHEMBL1520472 | 0.69 | NLRP3 (0.40) | NLRP3SLC6A2SLC6A4SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3116873-B1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | ABBVIE DEUTSCHLAND (DE) | 2018-02-28 | — | — | EP | disclosed |
| US-20170158693-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | ABBVIE DEUTSCHLAND (DE) | 2017-06-08 | — | — | US | disclosed |
| US-9573950-B2 | Substituted [1,4]diazepino[6,7,1-ij]quinolines as serotonin 5-HT2C receptor modulators | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2017-02-21 | — | — | US | disclosed |
| EP-3116873-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-01-18 | — | — | EP | disclosed |
| US-20150259343-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2015136090-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158693-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | HTR2C, HTR2A, HTR5A | NLRP3 1052/4885F12 3333/4885F2 3265/4885 |
| US-20150259343-A1 | HEXAHYDRODIAZEPINOQUINOLINES CARRYING A CYCLIC RADICAL | HTR2C, HTR2A, HTR5A | NLRP3 1052/4885F12 3333/4885F2 3265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.